文献速递关节外科

加巴喷丁类药物与全髋/膝关节置换术后肺部并发症的剂量依赖性关联

Dose-Dependent Association of Gabapentinoids with Pulmonary Complications After Total Hip and Knee Arthroplasties.
PubMed 文献 · J Bone Joint Surg Am · 2020-01-01

本研究基于Premier数据库分析2009至2014年858,306例择期初次全髋或膝关节置换术成人患者,发现手术当日使用加巴喷丁或普瑞巴林任何剂量均与术后肺部并发症风险增加相关,且呈剂量反应关系,而对围手术期阿片类药物消耗或住院时长无临床意义的影响。

要点

  • 手术当日使用加巴喷丁或普瑞巴林任何剂量均与术后肺部并发症风险增加相关。
  • 加巴喷丁>1,050 mg/天时肺部并发症比值比为1.51(95%CI 1.40-1.63)。
  • 普瑞巴林>250 mg/天时肺部并发症比值比为1.81(95%CI 1.57-2.09)。

核心结论

  • 全髋或膝关节置换术当日使用加巴喷丁或普瑞巴林任何剂量与术后肺部并发症风险增加呈剂量反应关系,且对围手术期阿片消耗影响极小。

研究设计与样本

  • 基于Premier数据库的回顾性队列研究,纳入2009至2014年接受择期初次全髋或膝关节置换术的成人患者共858,306例。

主要发现

  • 11.0%患者接受加巴喷丁,10.2%接受普瑞巴林;患者平均年龄65.6±10.7岁,39.6%为男性,78.2%为白种人,55.2%为Medicare保险。
  • 与未使用相应药物相比,加巴喷丁>1,050 mg/天组术后肺部并发症比值比为1.51(95%CI 1.40-1.63)。
  • 与未使用相应药物相比,普瑞巴林>250 mg/天组术后肺部并发症比值比为1.81(95%CI 1.57-2.09)。
  • 加巴喷丁或普瑞巴林暴露与围手术期阿片消耗或住院时长无临床意义关联。

关键数值与推荐

  • 加巴喷丁剂量分组:无、1-350、351-700、701-1,050、>1,050 mg/天。
  • 普瑞巴林剂量分组:无、1-110、111-250、>250 mg/天。
  • 主要结局为术后肺部并发症复合终点,包括呼吸衰竭、肺炎、再插管、肺水肿、无创通气或有创机械通气。

临床怎么用

  • 在全髋或膝关节置换术围手术期使用加巴喷丁类药物时,应权衡其增加术后肺部并发症的剂量依赖性风险与有限的阿片节省效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gabapentinoids are commonly prescribed in perioperative multimodal analgesia protocols. Despite widespread use, the optimal dose to reduce opioid consumption while minimizing risks is unknown. We assessed dose-dependent effects of gabapentinoids on opioid consumption and postoperative pulmonary complications following total hip or knee arthroplasty (THA or TKA). We hypothesized that use of a gabapentinoid on the day of THA or TKA is associated with an increased risk of postoperative pulmonary complications in a dose-response fashion compared with the risk for patients who did not receive the drug. METHODS: Using the Premier Database, we identified adults who underwent elective primary THA or TKA from 2009 to 2014. The exposure was receipt of a gabapentinoid (gabapentin or pregabalin) on the day of surgery. Gabapentin dose was categorized into 5 groups: none, 1 to 350, 351 to 700, 701 to 1,050, and >1,050 mg per day. Pregabalin dose was categorized into 4 groups: none, 1 to 110, 111 to 250, and >250 mg per day. The primary outcome was a composite of postoperative pulmonary complications, defined as respiratory failure, pneumonia, reintubation, pulmonary edema, noninvasive ventilation, or invasive mechanical ventilation. RESULTS: Of 858,306 patients who underwent THA or TKA, 11.0% received gabapentin and 10.2% received pregabalin. The mean age (and standard deviation) of the patients was 65.6 ± 10.7 years, 39.6% were male, 78.2% were Caucasian, and 55.2% were covered by Medicare. In multilevel regression analysis, receipt of gabapentinoid at any dose on the day of surgery was associated with increased odds of postoperative pulmonary complications. Compared with no exposure to the drug being used by the particular group, all dose ranges of gabapentin and pregabalin were associated with greater odds of postoperative pulmonary complications (odds ratio, 95% confidence interval = 1.51, 1.40 to 1.63, for >1,050 mg of gabapentin and 1.81, 1.57 to 2.09, for >250 mg of pregabalin). We found no clinically meaningful associations between exposure to either gabapentin or pregabalin and perioperative opioid consumption or the length of the hospital stay. CONCLUSIONS: Exposure to gabapentinoids at any dose on the day of THA or TKA was associated with increased odds of postoperative pulmonary complications in a dose-response fashion, with minimal effects on perioperative opioid consumption. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Ohnuma T, Raghunathan K, Moore S, et al. Dose-Dependent Association of Gabapentinoids with Pulmonary Complications After Total Hip and Knee Arthroplasties. J Bone Joint Surg Am. 2020. PMID: 31804238. doi:10.2106/JBJS.19.00889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。